Challenges of Managing NF1-Related Plexiform Neurofibromas (NF1-PN)
Are you and your HCP often in agreement with your treatment plan for neurofibromatosis type 1 (NF1) or neurofibromatosis type…
Read More
Are you and your HCP often in agreement with your treatment plan for neurofibromatosis type 1 (NF1) or neurofibromatosis type…
Read More
They gave 10 AMAZING YEARS to the cause and raised a lot of funds. Thank you to the Oswald family…
Read More
If you or someone you love has neurofibromatosis type 1 (NF1), it’s important to know that women with NF1 between…
Read More
SpringWorks Sponsorship Brings Hope and Support to the NF Community We are excited to share some wonderful news — SpringWorks Therapeutics is…
Read More
Back-to-school season brings new routines, new teachers, and sometimes new challenges for families living with neurofibromatosis (NF). That’s why we’re…
Read More
Are you a passionate young adult looking to make a difference in your community? The NF Young Adult Leadership Program…
Read More
The European Commission has granted conditional approval for EZMEKLY® (mirdametinib) to treat symptomatic, inoperable plexiform neurofibromas (PNs) in patients aged…
Read More
I Just Joined the NF1-TED Study — and You Might Want To, Too I recently enrolled in the NF1 Tumor…
Read More
Started in 2004, Camp NF (originally Camp New Friends) is a condition-specific camp for children with NF (including NF2-SWN and…
Read More
This May, NF Midwest, and other NF organizations are coming together to turn awareness into action. We’re turning up the…
Read More
© 2025 Neurofibromatosis Midwest - non profit 501(c)(t3). Site Map - Privacy Policy
The resources on this site should not be used as a substitute for professional medical care or advice on Neurofibromatosis. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional.